Myeloma cells in MM patients extensively secrete DKK1 to inhibit proliferation of mesenchymal stem cells (MSC) or early-stage osteoprogenitors, leading to decreased bone formation at osteolytic bone. Here, DKK1 is linked to plasma cell myeloma.